Results 131 to 140 of about 4,368 (233)

Pegvisomant in acromegaly: a multicenter real-life study in Argentina

Archives of Endocrinology and Metabolism
Objective To describe the long term safety and efficacy of pegvisomant (PEGV), and the predictors of treatment response in patients with acromegaly in the real life setting.
Natalia Ximena Garcia Basavilbaso, Maria Carolina Ballarino, Darío Bruera, Oscar D. Bruno, Alberto B. Chervin, Karina Danilowicz, Patricia Fainstein-Day, Silvina Gabriela Fidalgo, Adriana Frigeri, Mariela Glerean, Rodolfo Guelman, Gabriel Isaac, Debora Adela Katz, Pablo Knoblovits, Fabiana Librandi, Monica López Montes, Maria Susana Mallea-Gil, Marcos Manavela, Paula Mereshian, Daniel Moncet, Analia Pignatta, Amelia Rogozinsky, Laura R. Sago, Marisa Servidio, Monica Spezzi, Graciela Stalldecker, Julieta Tkatch, Nicolas Marcelo Vitale, Mirtha Guitelman   +28 more
doaj   +1 more source

Therapeutic options in the management of acromegaly: focus on lanreotide Autogel®

Biologics: Targets & Therapy, 2008
Ferdinand Roelfsema, Nienke R Biermasz, Alberto M Pereira, Johannes A RomijnDepartment of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, The NetherlandsBackground: In acromegaly, expert surgery is curative in only about 60% of ...
Ferdin, Roelfsema, Nienke R Biermasz, Alberto M Pereira, Johannes A Romijn   +4 more
doaj  

The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis [PDF]

, 2016
Sanne Franck, Linda Broer, Aart Jan van der Lely, Peter Kamenický, Ignacio Bernabéu, Elena Malchiodi, Patric J. D. Delhanty, Fernando Rivadeneira, Sebastian Neggers   +8 more
openalex   +1 more source

Pegvisomant [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study. [PDF]

, 2008
Ursula Plöckinger, T Reuter
openalex   +1 more source

Abstracts

Molecular Oncology, Volume 18, Issue S1, Page 1-495, June 2024.
wiley   +1 more source

Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis [PDF]

, 2016
Nicholas A. Tritos, Philippe Chanson, Camilo Jiménez, Donna King, Peter Jönsson, Anne Klibanski, Beverly M. K. Biller   +6 more
openalex   +1 more source

Effects of treatment for acromegaly on Bone Mineral Density (BMD): is Pegvisomant protective on lumbar BMD? [PDF]

, 2013
The abstract deals with the different effects of treatments for acromegaly on ...
BRIGANTE, Giulia, CARANI, Cesare, DIAZZI, Chiara, G. Ferrannini, MADEO, Bruno, ROCHIRA, Vincenzo, S. De Vincentis, SANTI, Daniele, SIMONI, Manuela   +8 more
core  

Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study

, 2019
Annamaria Colao, Wojciech Zgliczyński, Jan Komorowski, Beata Kos‐Kudła, Antoine Tabarin, V. Kerlan, Francesco Minuto, Carla Scaroni, Marek Bolanowski   +8 more
openalex   +2 more sources

Case Report: Persistent Acromegaly – Effective Therapy with Lanreotide and Weekly Pegvisomant Injections [PDF]

, 2018
Thomas H. Schürmeyer, Britta Galling
openalex   +1 more source